using the new oral anticoagulants (Pradaxa, Xarelto, Eliquis) for "off-label" uses

April 2013

Questions are coming up about using the new oral anticoagulants (Pradaxa, Xarelto, Eliquis) for "off-label" uses.

All are approved to prevent stroke in nonvalvular atrial fib.

Xarelto (rivaroxaban) is also approved to prevent thrombosis after hip or knee surgery...or to treat venous thromboembolism.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote